{"id":60712,"date":"2025-01-31T07:02:35","date_gmt":"2025-01-31T06:02:35","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/daiichi-sankyo-appoints-hiroyuki-okuzawa-as-chief-executive-officer\/"},"modified":"2025-01-31T07:02:35","modified_gmt":"2025-01-31T06:02:35","slug":"daiichi-sankyo-appoints-hiroyuki-okuzawa-as-chief-executive-officer","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/daiichi-sankyo-appoints-hiroyuki-okuzawa-as-chief-executive-officer\/","title":{"rendered":"Daiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive Officer"},"content":{"rendered":"
\n

TOKYO–(BUSINESS WIRE)–Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effective April 1, 2025.<\/p>\n

<\/a>
<\/a><\/p>\n

\nDr. Manabe will transition from his current role of Representative Director, Executive Chairperson and CEO to Representative Director and Executive Chairperson while Mr. Okuzawa will transition to Representative Director, President and CEO.<\/p>\n

\nUnder Dr. Manabe\u2019s leadership, Daiichi Sankyo\u2019s pioneering science and technology led to the resurgence of antibody drug conjugate (ADC) development within the pharmaceutical industry, leading to three of the largest licensing deals in history along with the approvals of ENHERTU\u00ae<\/sup> and DATROWAY\u00ae<\/sup>, two precision cancer medicines invented with Daiichi Sankyo\u2019s DXd ADC Technology that are changing the way that metastatic breast cancer is treated.<\/p>\n

\nDaiichi Sankyo\u2019s five-year business plan (FY2021-2025) is progressing successfully with the rapid and global expansion of its oncology business. In order to ensure the solid achievement of FY2025 goals and to strengthen its management structure, Daiichi Sankyo\u2019s Board of Directors appointed Mr. Okuzawa as the new CEO at the board meeting on January 31, 2025, based on the Nomination Committee\u2019s report. This transition in April 2025 will occur as Daiichi Sankyo enters the final year of its current five-year business plan and it starts full scale preparation for the next five-year business plan (FY2026-2030).<\/p>\n

\nMr. Okuzawa joined Daiichi Sankyo in 1986 and has served as Representative Director, President and Chief Operating Officer (COO) since 2023. He also held the role of Chief Financial Officer (CFO) for two years and other senior leadership roles in international business, corporate strategy and human resources during his tenure at Daiichi Sankyo. Mr. Okuzawa graduated from Hitotsubashi University in Tokyo with a degree in Social Sciences. Mr. Okuzawa has 50,741 shares of the company as of September 30, 2024.<\/p>\n

\n\u201cHiroyuki Okuzawa has played a pivotal role in advancing our current five-year business plan, driving unprecedented global growth for our company,\u201d said Sunao Manabe. \u201cBeyond his extensive experience as an international business leader and impressive accomplishments while serving as both COO and CFO at Daiichi Sankyo, Hiroyuki has been a key figure in transforming our corporate culture by exemplifying our core behaviors of inclusivity and diversity, collaboration and trust, and continuous development and growth. As the new CEO, I am confident that Hiroyuki will continue to provide strong leadership, propelling Daiichi Sankyo to the forefront of the global pharmaceutical industry by enhancing patient care worldwide through creating new medicines with our expertise in science and technology.\u201d<\/p>\n

\n\u201cI am deeply honored to be the next CEO of Daiichi Sankyo and will follow Sunao Manabe\u2019s exceptional leadership and unwavering commitment to patients and their families,\u201d said Hiroyuki Okuzawa. \u201cBuilding on this foundation, I will continue to leverage Daiichi Sankyo\u2019s strengths in science and technology, and will continuously develop our talent globally. Under my leadership, we will create a 2035 vision and a next five-year business plan (FY2026-2030), continuing to enrich the quality of life worldwide.\u201d<\/p>\n

\nAbout Daiichi Sankyo
\n
<\/b>Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and other diseases with high unmet medical need. For more information, please visit www.daiichisankyo.com<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia Contacts:<\/b>
Daiichi Sankyo Co., Ltd.
\n
DS-PR_jp@daiichisankyo.com<\/a><\/p>\n

\nInvestor Relations Contact:<\/b>
DaiichiSankyoIR_jp@daiichisankyo.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

TOKYO–(BUSINESS WIRE)–Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effective April 1, 2025. Dr. Manabe will transition from his current role of Representative Director, Executive Chairperson and CEO to Representative Director and Executive Chairperson while Mr. Okuzawa will transition to Representative … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-60712","6":"format-standard","7":"category-industry"},"yoast_head":"\nDaiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive Officer - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/daiichi-sankyo-appoints-hiroyuki-okuzawa-as-chief-executive-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Daiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive Officer - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"TOKYO–(BUSINESS WIRE)–Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effective April 1, 2025. Dr. Manabe will transition from his current role of Representative Director, Executive Chairperson and CEO to Representative Director and Executive Chairperson while Mr. Okuzawa will transition to Representative ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/daiichi-sankyo-appoints-hiroyuki-okuzawa-as-chief-executive-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-31T06:02:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250130225103\/en\/2350376\/22\/DS_logo_portrait_format_4color_rgb_120206.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/daiichi-sankyo-appoints-hiroyuki-okuzawa-as-chief-executive-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/daiichi-sankyo-appoints-hiroyuki-okuzawa-as-chief-executive-officer\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Daiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive Officer\",\"datePublished\":\"2025-01-31T06:02:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/daiichi-sankyo-appoints-hiroyuki-okuzawa-as-chief-executive-officer\\\/\"},\"wordCount\":596,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/daiichi-sankyo-appoints-hiroyuki-okuzawa-as-chief-executive-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250130225103\\\/en\\\/2350376\\\/22\\\/DS_logo_portrait_format_4color_rgb_120206.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/daiichi-sankyo-appoints-hiroyuki-okuzawa-as-chief-executive-officer\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/daiichi-sankyo-appoints-hiroyuki-okuzawa-as-chief-executive-officer\\\/\",\"name\":\"Daiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive Officer - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/daiichi-sankyo-appoints-hiroyuki-okuzawa-as-chief-executive-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/daiichi-sankyo-appoints-hiroyuki-okuzawa-as-chief-executive-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250130225103\\\/en\\\/2350376\\\/22\\\/DS_logo_portrait_format_4color_rgb_120206.jpg\",\"datePublished\":\"2025-01-31T06:02:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/daiichi-sankyo-appoints-hiroyuki-okuzawa-as-chief-executive-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/daiichi-sankyo-appoints-hiroyuki-okuzawa-as-chief-executive-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/daiichi-sankyo-appoints-hiroyuki-okuzawa-as-chief-executive-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250130225103\\\/en\\\/2350376\\\/22\\\/DS_logo_portrait_format_4color_rgb_120206.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250130225103\\\/en\\\/2350376\\\/22\\\/DS_logo_portrait_format_4color_rgb_120206.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/daiichi-sankyo-appoints-hiroyuki-okuzawa-as-chief-executive-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Daiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Daiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive Officer - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/daiichi-sankyo-appoints-hiroyuki-okuzawa-as-chief-executive-officer\/","og_locale":"en_US","og_type":"article","og_title":"Daiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive Officer - Pharma Trend","og_description":"TOKYO–(BUSINESS WIRE)–Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effective April 1, 2025. Dr. Manabe will transition from his current role of Representative Director, Executive Chairperson and CEO to Representative Director and Executive Chairperson while Mr. Okuzawa will transition to Representative ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/daiichi-sankyo-appoints-hiroyuki-okuzawa-as-chief-executive-officer\/","og_site_name":"Pharma Trend","article_published_time":"2025-01-31T06:02:35+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250130225103\/en\/2350376\/22\/DS_logo_portrait_format_4color_rgb_120206.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/daiichi-sankyo-appoints-hiroyuki-okuzawa-as-chief-executive-officer\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/daiichi-sankyo-appoints-hiroyuki-okuzawa-as-chief-executive-officer\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Daiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive Officer","datePublished":"2025-01-31T06:02:35+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/daiichi-sankyo-appoints-hiroyuki-okuzawa-as-chief-executive-officer\/"},"wordCount":596,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/daiichi-sankyo-appoints-hiroyuki-okuzawa-as-chief-executive-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250130225103\/en\/2350376\/22\/DS_logo_portrait_format_4color_rgb_120206.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/daiichi-sankyo-appoints-hiroyuki-okuzawa-as-chief-executive-officer\/","url":"https:\/\/pharma-trend.com\/en\/daiichi-sankyo-appoints-hiroyuki-okuzawa-as-chief-executive-officer\/","name":"Daiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive Officer - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/daiichi-sankyo-appoints-hiroyuki-okuzawa-as-chief-executive-officer\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/daiichi-sankyo-appoints-hiroyuki-okuzawa-as-chief-executive-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250130225103\/en\/2350376\/22\/DS_logo_portrait_format_4color_rgb_120206.jpg","datePublished":"2025-01-31T06:02:35+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/daiichi-sankyo-appoints-hiroyuki-okuzawa-as-chief-executive-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/daiichi-sankyo-appoints-hiroyuki-okuzawa-as-chief-executive-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/daiichi-sankyo-appoints-hiroyuki-okuzawa-as-chief-executive-officer\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250130225103\/en\/2350376\/22\/DS_logo_portrait_format_4color_rgb_120206.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250130225103\/en\/2350376\/22\/DS_logo_portrait_format_4color_rgb_120206.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/daiichi-sankyo-appoints-hiroyuki-okuzawa-as-chief-executive-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Daiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive Officer"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60712","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=60712"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60712\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=60712"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=60712"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=60712"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}